TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.

Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows:

Date:

Friday, February 11, 2022

Time:

8:30 AM ET

Toll-free (U.S.)

(866) 601-3896

International

(636) 812-6499

Conference ID

1286376

The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to lwilson@insitecony.com. The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022.

About TYME Technologies, Inc. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to cause cancer cell death.

The Company is currently focused on developing its novel compound, SM-88. The Company believes that early clinical results demonstrated by SM-88 in multiple advanced cancers, including prostate, sarcomas and breast, reinforce the potential of its emerging CMBT™ pipeline.

For more information about the Company, visit www.tymeinc.com and connect on Facebook, LinkedIn, and Twitter.

Forward-Looking Statements In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. The forward-looking statements contained in this press release are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of TYME's control. Factors that could cause actual results to differ materially from these forward-looking statements include the Company’s ability to successfully implement its clinical and other plans, competitive and regulatory developments, and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form

10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on June 10, 2021, as well as subsequent reports and filings from time to time with the SEC.

The information contained in this press release is as of the release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

INVESTOR AND MEDIA: In-Site Communications Lisa M. Wilson T: 212-452-2793 E: lwilson@insitecony.com

Tyme Technologies (NASDAQ:TYME)
過去 株価チャート
から 10 2024 まで 11 2024 Tyme Technologiesのチャートをもっと見るにはこちらをクリック
Tyme Technologies (NASDAQ:TYME)
過去 株価チャート
から 11 2023 まで 11 2024 Tyme Technologiesのチャートをもっと見るにはこちらをクリック